322 related articles for article (PubMed ID: 35032137)
41. Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis.
Minard LV; Corkum A; Sketris I; Fisher J; Zhang Y; Saleh A
PLoS One; 2016; 11(7):e0158608. PubMed ID: 27434392
[TBL] [Abstract][Full Text] [Related]
42. Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition.
Hu M; Mak VW; Tomlinson B
J Clin Pharm Ther; 2011 Jun; 36(3):419-25. PubMed ID: 21545622
[TBL] [Abstract][Full Text] [Related]
43. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
Insull W; Ghali JK; Hassman DR; Y As JW; Gandhi SK; Miller E;
Mayo Clin Proc; 2007 May; 82(5):543-50. PubMed ID: 17493418
[TBL] [Abstract][Full Text] [Related]
44. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
Atherosclerosis; 2015 Aug; 241(2):450-4. PubMed ID: 26074319
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
Younis I; Weber E; Nelson C; Kirby BJ; Shen G; Xiao D; Watkins TR; Othman AA
Clin Pharmacokinet; 2023 Apr; 62(4):609-621. PubMed ID: 36906733
[TBL] [Abstract][Full Text] [Related]
46. Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia.
Climent E; Marco-Benedí V; Benaiges D; Pintó X; Suárez-Tembra M; Plana N; Lafuente H; Ortega-Martínez de Victoria E; Brea-Hernando Á; Vila À; Civeira F; Pedro-Botet J
Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1594-1603. PubMed ID: 33744038
[TBL] [Abstract][Full Text] [Related]
47. Rosuvastatin: a review of its use in the management of dyslipidemia.
Scott LJ; Curran MP; Figgitt DP
Am J Cardiovasc Drugs; 2004; 4(2):117-38. PubMed ID: 15049723
[TBL] [Abstract][Full Text] [Related]
48. Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882.
Dingemanse J; Nicolas LB; van Bortel L
Eur J Clin Pharmacol; 2014 Jun; 70(6):675-84. PubMed ID: 24728182
[TBL] [Abstract][Full Text] [Related]
49. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Saw J; Steinhubl SR; Berger PB; Kereiakes DJ; Serebruany VL; Brennan D; Topol EJ;
Circulation; 2003 Aug; 108(8):921-4. PubMed ID: 12925453
[TBL] [Abstract][Full Text] [Related]
50. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.
Schmidt GA; Hoehns JD; Purcell JL; Friedman RL; Elhawi Y
J Am Board Fam Med; 2007; 20(4):411-6. PubMed ID: 17615423
[TBL] [Abstract][Full Text] [Related]
51. [Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain].
Cosin Sales J; Fuentes Jiménez FJ; Mantilla Morató T; Ruiz E; Becerra V; Aceituno S; Ferrario MG; Lizán L; Gracia A
Clin Investig Arterioscler; 2015; 27(5):228-38. PubMed ID: 25640158
[TBL] [Abstract][Full Text] [Related]
52. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs.
Akimoto H; Negishi A; Oshima S; Okita M; Numajiri S; Inoue N; Ohshima S; Kobayashi D
Pharmacol Res Perspect; 2018 Dec; 6(6):e00439. PubMed ID: 30443347
[TBL] [Abstract][Full Text] [Related]
53. Statin use in Australian children: a retrospective audit of four pediatric hospitals.
Gelissen IC; Nguyen HL; Tiao DK; Ayoub R; Aslani P; Moles R
Paediatr Drugs; 2014 Oct; 16(5):417-23. PubMed ID: 25164329
[TBL] [Abstract][Full Text] [Related]
54. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.
Karlson BW; Wiklund O; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
Eur Heart J Cardiovasc Pharmacother; 2016 Oct; 2(4):212-7. PubMed ID: 27533947
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
Bener A; Dogan M; Barakat L; Al-Hamaq AO
J Prim Care Community Health; 2014 Jul; 5(3):180-7. PubMed ID: 24522932
[TBL] [Abstract][Full Text] [Related]
56. Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg.
Stein B; Ward T; Hale G; Lyver E
Ann Pharmacother; 2020 May; 54(5):405-413. PubMed ID: 31718234
[No Abstract] [Full Text] [Related]
57. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database.
Hsieh HC; Hsu JC; Lu CY
BMJ Open; 2017 May; 7(5):e014150. PubMed ID: 28515189
[TBL] [Abstract][Full Text] [Related]
58. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
Wang E; Casciano CN; Clement RP; Johnson WW
Pharm Res; 2001 Jun; 18(6):800-6. PubMed ID: 11474784
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the pleiotropic effect of atorvastatin and rosuvastatin on postmenopausal changes in bone turnover: A randomized comparative study.
Braszak-Cymerman A; Walczak MK; Oduah MT; Ludziejewska A; Bryl W
Medicine (Baltimore); 2024 May; 103(19):e38122. PubMed ID: 38728464
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
